Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGIK2001 Phase II platinum–etoposide plus durvalumab for ED-SCLC with untreated brain metastases
jRCTs071210036Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, cisplatin, etoposide and durvalumab in small cell lung cancer (SCLC) and brain metastases, sponsored by AstraZeneca. Primary endpoint: Response rate of brain metastasis. Started Jun 2021; status: completed.
02
Drugs
carboplatincisplatinetoposidedurvalumab
03
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on jRCTs071210036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210036.